tetano
Editor, Senior Moderator
PLoS One
. 2022 Apr 28;17(4):e0267038.
doi: 10.1371/journal.pone.0267038. eCollection 2022.
Remdesivir plus Dexamethasone in COVID-19: A cohort study of severe patients requiring high flow oxygen therapy or non-invasive ventilation
Gennaro De Pascale[SUP] 1 2 [/SUP], Salvatore Lucio Cutuli[SUP] 1 2 [/SUP], Simone Carelli[SUP] 1 2 [/SUP], Rikardo Xhemalaj[SUP] 1 2 [/SUP], Tommaso Rosà[SUP] 1 2 [/SUP], Giuseppe Bello[SUP] 1 2 [/SUP], Joel Vargas[SUP] 1 2 [/SUP], Melania Cesarano[SUP] 1 2 [/SUP], Luca Montini[SUP] 1 2 [/SUP], Eloisa Sofia Tanzarella[SUP] 1 2 [/SUP], Gabriele Pintaudi[SUP] 1 2 [/SUP], Mariangela Di Muro[SUP] 1 2 [/SUP], Domenico Luca Grieco[SUP] 1 2 [/SUP], Massimo Antonelli[SUP] 1 2 [/SUP]
Affiliations
Abstract
Introduction: Remdesivir and Dexamethasone represent the cornerstone of therapy for critically ill patients with acute hypoxemic respiratory failure caused by Coronavirus Disease 2019 (COVID-19). However, clinical efficacy and safety of concomitant administration of Remdesivir and Dexamethasone (Rem-Dexa) in severe COVID-19 patients on high flow oxygen therapy (HFOT) or non-invasive ventilation (NIV) remains unknown.
Materials and methods: Prospective cohort study that was performed in two medical Intensive Care Units (ICUs) of a tertiary university hospital. The clinical impact of Rem-Dexa administration in hypoxemic patients with COVID-19, who required NIV or HFOT and selected on the simplified acute physiology score II, the sequential organ failure assessment score and the Charlson Comorbidity Index score, was investigated. The primary outcome was 28-day intubation rate; secondary outcomes were end-of-treatment clinical improvement and PaO2/FiO2 ratio, laboratory abnormalities and clinical complications, ICU and hospital length of stay, 28-day and 90-day mortality.
Results: We included 132 patients and found that 28-day intubation rate was significantly lower among Rem-Dexa group (19.7% vs 48.5%, p<0.01). Although the end-of-treatment clinical improvement was larger among Rem-Dexa group (69.7% vs 51.5%, p = 0.05), the 28-day and 90-day mortalities were similar (4.5% and 10.6% vs. 15.2% and 16.7%; p = 0.08 and p = 0.45, respectively). The logistic regression and Cox-regression models showed that concomitant Rem-Dexa therapy was associated with a reduction of 28-day intubation rate (OR 0.22, CI95% 0.05-0.94, p = 0.04), in absence of laboratory abnormalities and clinical complications (p = ns).
Conclusions: In COVID-19 critically ill patients receiving HFO or NIV, 28-day intubation rate was lower in patients who received Rem-Dexa and this finding corresponded to lower end-of-treatment clinical improvement. The individual contribution of either Remdesevir or Dexamethasone to the observed clinical effect should be further investigated.
. 2022 Apr 28;17(4):e0267038.
doi: 10.1371/journal.pone.0267038. eCollection 2022.
Remdesivir plus Dexamethasone in COVID-19: A cohort study of severe patients requiring high flow oxygen therapy or non-invasive ventilation
Gennaro De Pascale[SUP] 1 2 [/SUP], Salvatore Lucio Cutuli[SUP] 1 2 [/SUP], Simone Carelli[SUP] 1 2 [/SUP], Rikardo Xhemalaj[SUP] 1 2 [/SUP], Tommaso Rosà[SUP] 1 2 [/SUP], Giuseppe Bello[SUP] 1 2 [/SUP], Joel Vargas[SUP] 1 2 [/SUP], Melania Cesarano[SUP] 1 2 [/SUP], Luca Montini[SUP] 1 2 [/SUP], Eloisa Sofia Tanzarella[SUP] 1 2 [/SUP], Gabriele Pintaudi[SUP] 1 2 [/SUP], Mariangela Di Muro[SUP] 1 2 [/SUP], Domenico Luca Grieco[SUP] 1 2 [/SUP], Massimo Antonelli[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35482703
- DOI: 10.1371/journal.pone.0267038
Abstract
Introduction: Remdesivir and Dexamethasone represent the cornerstone of therapy for critically ill patients with acute hypoxemic respiratory failure caused by Coronavirus Disease 2019 (COVID-19). However, clinical efficacy and safety of concomitant administration of Remdesivir and Dexamethasone (Rem-Dexa) in severe COVID-19 patients on high flow oxygen therapy (HFOT) or non-invasive ventilation (NIV) remains unknown.
Materials and methods: Prospective cohort study that was performed in two medical Intensive Care Units (ICUs) of a tertiary university hospital. The clinical impact of Rem-Dexa administration in hypoxemic patients with COVID-19, who required NIV or HFOT and selected on the simplified acute physiology score II, the sequential organ failure assessment score and the Charlson Comorbidity Index score, was investigated. The primary outcome was 28-day intubation rate; secondary outcomes were end-of-treatment clinical improvement and PaO2/FiO2 ratio, laboratory abnormalities and clinical complications, ICU and hospital length of stay, 28-day and 90-day mortality.
Results: We included 132 patients and found that 28-day intubation rate was significantly lower among Rem-Dexa group (19.7% vs 48.5%, p<0.01). Although the end-of-treatment clinical improvement was larger among Rem-Dexa group (69.7% vs 51.5%, p = 0.05), the 28-day and 90-day mortalities were similar (4.5% and 10.6% vs. 15.2% and 16.7%; p = 0.08 and p = 0.45, respectively). The logistic regression and Cox-regression models showed that concomitant Rem-Dexa therapy was associated with a reduction of 28-day intubation rate (OR 0.22, CI95% 0.05-0.94, p = 0.04), in absence of laboratory abnormalities and clinical complications (p = ns).
Conclusions: In COVID-19 critically ill patients receiving HFO or NIV, 28-day intubation rate was lower in patients who received Rem-Dexa and this finding corresponded to lower end-of-treatment clinical improvement. The individual contribution of either Remdesevir or Dexamethasone to the observed clinical effect should be further investigated.